EN DE
Watch OmniAb Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

OmniAb Inc. (OABI) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of OmniAb Inc. stock $3.72, price $5.10, that is 27.1% below the price, quality 30 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

OI OmniAb Inc. logo Thin data Nov 11, 2026

OmniAb Inc.

OABI · US
Expensive, weak quality

Our calculation puts a fair price 27% below what the stock costs today.

Generates free cash flow over the last twelve months
Revenue last quarter +78% vs. a year ago.
Fair value $3.72 · Overvalued
Quality 30/100
Weak Growth (revenue 5y −4.3 %/yr in USD)
Loss-making · -108.1% net margin (TTM)
Trails peers (3/8)
Narrow moat 12/100
Thin data
Estimate
Watch OmniAb Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$10.31 $1.25 Fair Value $3.72 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $1.25 – $10.31 · fair‑value band $2.79 – $4.64 · the $5.10 price screens above the $3.72 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow OmniAb in your weekly email

Every Wednesday you see whether OmniAb is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.

Show moreShow less

The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.

Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics.

The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities.

It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Stock analysis

OmniAb Inc. (OABI) currently trades at $5.10, while our estimate is $3.72, 27% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $2.79 (bear) to $4.64 (bull), the price of $5.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

OmniAb Inc. reported revenue of $18.7M in FY2025 versus $34.7M in FY2021, a compound −14.4%/yr. Reported net income was −$64.8M in FY2025.

Key figures

Market cap $773M Small · P/S ratio 19.2 · EPS (TTM) $−0.3400 · Net margin −108% · Return on equity −16.5% · Return on assets (EBIT) −16.6% (5-year average) · Operating margin −410% · Revenue (TTM) $40.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 4% below its 52-week high and 275% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −27%, OABI screens richer than that median.

Fair Value

Bear $2.79 Fair Value $3.72 Bull $4.64
Price $5.10 · Downside -27.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 13
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 82
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 17
How calm the share price moves, does not count
Price momentum 100
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 98
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleCharles S BerkmanChief Legal Officer4× since Dec 8, 2025: 31,864 shares, avg. $1.72$54,854Apr 7, 2026
  • SaleKurt A GustafsonExecutive VP, Finance and CFO4× since Dec 8, 2025: 46,964 shares, avg. $1.80$84,700Apr 7, 2026
  • SaleMatthew W FoehrPresident and CEO, Director4× since Dec 8, 2025: 84,507 shares, avg. $1.70$143,482Apr 7, 2026

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−29.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−31.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−110.1% (2020) → −383.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

OABI screens overvalued: fair value 27% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare OmniAb Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −27.1% · Below median
Profitability
Return on assets −21.5% · Above median
Net margin (12 months) −108.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 78.3% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.90× · Pricier than median
P/S (12 months) 19.23× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs OABI
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs OABI
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs OABI
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs OABI
argenx SE ARGX $971.55 $908.40 −7% vs OABI
CSL Limited CSL A$201.68 A$181.40 −10% vs OABI
Moderna, Inc MRNA $250.83 $158.70 −37% vs OABI
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs OABI
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs OABI
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs OABI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

OmniAb Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "OmniAb Inc. Fair Value". https://www.fairvalue-calculator.com/stock/OABI

Frequently asked questions

Is OmniAb Inc. (OABI) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $3.72 versus a price of $5.10, about 27% lower (overvalued).
What is the fair value of OABI?
Our estimate for OmniAb Inc. is $3.72 (as of Nov 11, 2026), built from audited fundamentals. The current price: $5.10.
What is the quality score of OABI?
OmniAb Inc. has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OmniAb Inc. (OABI)?
Our calculated price target is the estimate of $3.72 (as of Nov 11, 2026). Cautious scenario $2.79, optimistic scenario $4.64. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the OmniAb Inc. stock forecast for 2026?
Our estimate puts fair value at $3.72, about 27% lower versus a price of $5.10 (overvalued). Cautious scenario $2.79, optimistic scenario $4.64. The calculation is refreshed regularly with new filings.
What is the revenue of OmniAb Inc. (OABI)?
OmniAb Inc. reported trailing-twelve-month revenue of about $40.2M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of OmniAb Inc. (OABI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OmniAb Inc. it is $3.72 per share (as of Nov 11, 2026), against a price of $5.10.
Is OmniAb Inc. stock overvalued or undervalued in 2026?
As of Nov 11, 2026, OABI trades above its calculated fair value: price $5.10, fair value $3.72, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OABI?
No. The price is what the market pays today ($5.10); the fair value is what the company's own numbers justify ($3.72). For OmniAb Inc. the two are $1.38 per share apart. That gap is exactly why we show both numbers side by side.
How much is OmniAb Inc. worth?
The market values OmniAb Inc. at about $773M (market capitalisation, as of Nov 11, 2026). Per share that is $5.10; our models calculate a fair value of $3.72 per share.
What do the bullish and bearish scenarios say about OABI?
Our models span a range for OmniAb Inc.: cautious scenario $2.79, base $3.72, optimistic $4.64 per share (as of Nov 11, 2026, price $5.10). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of OmniAb Inc. (OABI)?
Balance-sheet figures for OmniAb Inc. (as of Nov 11, 2026): return on equity −16.5%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is OABI from its 52-week high?
OmniAb Inc. trades at $5.10, about 4% below its 52-week high of $5.30 and 275% above the low of $1.36 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $3.72 is for.
Which stocks are comparable to OmniAb Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OmniAb Inc. stock attractive at the current price?
The data as of Nov 11, 2026: price $5.10, calculated fair value $3.72 (−27%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. OmniAb Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OmniAb Inc. (OABI)?
The closing price on Nov 10, 2026 was $5.10. Our estimate is $3.72, about 27% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OmniAb Inc. right now?
The price sits above even our optimistic bull case ($4.64). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of OmniAb Inc.

How large is the market capitalisation of OmniAb Inc. (OABI)?
The market capitalisation of OmniAb Inc. is $773M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of OmniAb Inc. (OABI)?
The price-to-sales ratio of OmniAb Inc. is 19.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of OmniAb Inc. (OABI)?
Earnings per share at OmniAb Inc. are $−0.3400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of OmniAb Inc. (OABI)?
The net margin of OmniAb Inc. is −108% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of OmniAb Inc. (OABI)?
The return on equity (ROE) of OmniAb Inc. is −16.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OmniAb Inc. (OABI)?
On an EBIT basis the return on assets of OmniAb Inc. is −16.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OmniAb Inc. (OABI)?
The operating margin of OmniAb Inc. is −410% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OmniAb Inc. (OABI)?
Revenue at OmniAb Inc. is growing +78.3% versus a year earlier (3y avg −31.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does OmniAb Inc. (OABI) generate?
The free cash flow of OmniAb Inc. is −$37.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does OmniAb Inc. (OABI) hold?
OmniAb Inc. holds more cash than debt, $5.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch OmniAb Inc. in the live analysis

One click puts OmniAb Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.